All News

Family members should also be trained in how to administer seizure first aid, apply a tourniquet to control bleeding, operate an automated external defibrillator, and perform cardiopulmonary resuscitation.

The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.

The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.

Andre Harvin, PharmD, MBA, discussed the use of immunotherapies in melanoma and broader challenges with access to oncology care in rural or underserved communities.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).

With immune checkpoint inhibitors in particular, patients are seeing greater results with fewer adverse effects.

Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.

Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.

VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.

Errors risk transmission of blood-borne pathogens, including HBV, HCV, HIV, to health care providers, patients.

Heidi Finnes, PharmD, BCOP, FHOPA, director of clinical ambulatory pharmacy practice at Mayo Clinic, discussed updates in melanoma and the use of immunotherapies and targeted therapies.

A single dose of axicabtagene ciloleucel in patients with large B-cell lymphoma led to significantly higher overall survival and progression-free survival rates, as well as improvements in quality of life and faster recovery in comparison to standard care therapy.

A plethora of targeted therapies, biomarker-driven therapies, and immunotherapies are now available.

Imposing the FDA on-label/off-label framework on administratively defined "children" resulted in a regulatory demand for pediatric studies that had no basis in clinical medicine, with the exception of the small group of preterm newborns.

Claire Biermaas, president of Corporate Partnerships at AmerisourceBergen, discussed the Corporate Partnerships Team, which works closely with pharmacy customers to guide their processes and help execute their vision.

Health care professionals can provide patients with tips on appropriate hand sanitizer use, as well as product recommendations.

Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.

Adult and maternal RSV vaccines reveal positive findings.

Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.

A lack of evidence of sex-specific recommendations results from a underrepresentation of women in cardiovascular disease-related trials.

Depression can affect the trajectory of treatment and associated outcomes.

Earlier in June, Govindan led an educational session about genomic testing at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Negative findings may spur choice of brand-name drugs, despite expense.

The folate alpha receptor (FRα) does have a toxicity profile, but unlike other chemotherapies, it does not severely compromise bone marrow and may improve ability to receive more therapies.

Study results indicate that taking these products together reduces the risk of rebound congestion typically seen with intranasal decongestant therapy.